Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of PM534 in Patients with Advanced Solid Tumors
2024-519013-57-00Phase 2Authorised
- Sponsor
- PharmaMar
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of PM534 in Nonhematologic neoplasms, sponsored by PharmaMar. Planned start Jun 2025; status: authorised.
02
Drugs
PM534
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2024-519013-57-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519013-57-00.